Public Comment and Testimony

Comment Before the FDA on the Use of Truvada as PrEP

May 10, 2012

"Truvada as PrEP introduces an important tool to address the HIV/AIDS epidemic in the United States."

TAI Public Comment to CDC/HRSA Advisory Committee on HIV, Hepatitis, and STD Prevention/treatment

November 16, 2011

A small ongoing work group should be formed composed of outside partners and HRSA/AIDS Bureau staff to work together to ensure health reform implementation goes as smoothly as possible for people with HIV.

TAI Public Comment to FDA Offers Strong Support for Renewal of the Prescription Drug User Fee Act

October 24, 2011

The AIDS Institute offers its strong support for the proposed recommendations of the fifth renewal of the Prescription Drug User Fee Act (PDUFA), as negotiated between the Federal Drug Administration (FDA) and the pharmaceutical industry.

Essential Health Benefits Public Comments before the Department of Health and Human Services

October 20, 2011

The Essential Health Benefits package must support the provision of high quality, comprehensive and affordable care not only for people living with HIV/AIDS but for all people who will be affected by it.

Syndicate content